0001193125-13-234866.txt : 20130628 0001193125-13-234866.hdr.sgml : 20130628 20130524110057 ACCESSION NUMBER: 0001193125-13-234866 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20130524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 430 CITY: BROOMFIELD STATE: CO ZIP: 80021 BUSINESS PHONE: 720-940-2200 MAIL ADDRESS: STREET 1: 8001 ARISTA PLACE STREET 2: SUITE 430 CITY: BROOMFIELD STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 CORRESP 1 filename1.htm CORRESP

May 24, 2013

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

 

Re: ARCA biopharma, Inc.
   Registration Statement on Form S-1
   Filed: March 25, 2013
   File No. 333-187508

Ladies and Gentlemen:

ARCA biopharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced filing to become effective at 4:00 p.m. Eastern Time on Wednesday, May 29, 2013, or as soon thereafter as is practicable.

The Company hereby acknowledges that:

 

  •  

should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

 

  •  

the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

 

  •  

the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Sincerely,

ARCA BIOPHARMA, INC.

 

By:       /s/ Patrick M. Wheeler
  Patrick M. Wheeler
  Chief Financial Officer

 

cc:   Jeffrey Riedler, Assistant Director, SEC
  Austin Stephenson, Esq., SEC
  Daniel Greenspan, Esq., SEC
  Brent D. Fassett, Esq., Cooley LLP